Goldman, Butterwick, Fitzpatrick and Groff

gbfg.com

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

41

Active

12

Phase 3

5

Total enrollment

939

Pipeline matrix

Showing 11 of 11 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Right leg treated with Glycerin compounded with 1% Lidocaine and Epinephrine1
Left leg treated with Glycerin compounded with 1% Lidocaine and Epinephrine1
Sham Comparator2
Right Arm treated with Active Re-Q Pro-Longevity Serum and Intense Pulsed Light Therapy1
Left Arm treated with vehicle serum and Intense Pulsed Light Therapy1
CE Ferulic1
Babor Ultimate ECM Repair Serum1
Babor Cure Cream1
Pavise Serum1
On GLP1 plus HRT1
On GLP1 Only1

Next readouts

  • 2024-12-31
  • 2025-03-05
  • 2026-05-30
  • 2026-07-30
  • 2026-08-30
  • 2026-11-10

Top conditions

  • Wrinkle5
  • Skin Laxity4
  • Laxity; Skin3
  • Photodamaged Skin2
  • Leg Veins2
  • Adiposity1
  • Improve Photoaging Signs1
  • Actinic Keratoses1

Frequently asked questions about Goldman, Butterwick, Fitzpatrick and Groff

How many clinical trials does Goldman, Butterwick, Fitzpatrick and Groff have on ClinicalTrials.gov?
Goldman, Butterwick, Fitzpatrick and Groff is listed as the lead sponsor on 41 clinical trials in ClinicalTrials.gov, 12 of which are currently active (recruiting, enrolling, or ongoing).
How many of Goldman, Butterwick, Fitzpatrick and Groff's trials are in Phase 3?
5 of Goldman, Butterwick, Fitzpatrick and Groff's trials are in Phase 3, spread across 11 active drug programs.
What therapeutic areas does Goldman, Butterwick, Fitzpatrick and Groff focus on?
Goldman, Butterwick, Fitzpatrick and Groff's most-studied conditions on ClinicalTrials.gov are Wrinkle, Skin Laxity, Laxity; Skin, Photodamaged Skin, Leg Veins.
When are Goldman, Butterwick, Fitzpatrick and Groff's next clinical trial readouts?
Goldman, Butterwick, Fitzpatrick and Groff has 6 upcoming primary-completion readouts tracked here; the soonest is “Skin Care Regimen for Improving Photoaging Signs on the Face”, expected around 2024-12-31.